771 related articles for article (PubMed ID: 31350639)
1. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
DiNardo C; Lachowiez C
Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
4. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
5. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
6. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with
Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U
Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101
[No Abstract] [Full Text] [Related]
8. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
[TBL] [Abstract][Full Text] [Related]
9. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
Bullinger L; Döhner K; Döhner H
J Clin Oncol; 2017 Mar; 35(9):934-946. PubMed ID: 28297624
[TBL] [Abstract][Full Text] [Related]
10. [Acute myeloid leukemia].
Döhner K; Paschka P; Döhner H
Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
[TBL] [Abstract][Full Text] [Related]
11. Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.
Richardson DR; Foster MC; Coombs CC; Zeidner JF
Semin Oncol Nurs; 2019 Dec; 35(6):150957. PubMed ID: 31759819
[TBL] [Abstract][Full Text] [Related]
12. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.
Heuser M; Mina A; Stein EM; Altman JK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():411-420. PubMed ID: 31099617
[TBL] [Abstract][Full Text] [Related]
13. Biological and clinical consequences of NPM1 mutations in AML.
Heath EM; Chan SM; Minden MD; Murphy T; Shlush LI; Schimmer AD
Leukemia; 2017 Apr; 31(4):798-807. PubMed ID: 28111462
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of
Ferret Y; Boissel N; Helevaut N; Madic J; Nibourel O; Marceau-Renaut A; Bucci M; Geffroy S; Celli-Lebras K; Castaigne S; Thomas X; Terré C; Dombret H; Preudhomme C; Renneville A
Haematologica; 2018 May; 103(5):822-829. PubMed ID: 29472349
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
19. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
20. [Precision medicine for acute myeloid leukemia based on genomic profiling].
Sanada M
Rinsho Ketsueki; 2019; 60(7):847-853. PubMed ID: 31391376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
